Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ocugen, Inc. Reports Favorable Safety and Tolerability Data for OCU410 in Phase 1/2 Clinical Trial for Geographic Atrophy Quiver Quantitative, Inc. - Thu Dec 19, 3:48PM CST

OCU410 shows promising safety and efficacy in treating geographic atrophy related to dry age-related macular degeneration.Quiver AI SummaryOcugen, Inc. announced that the Data and Safety Monitoring Board...

OCGN : 0.7743 (+0.83%)
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GlobeNewswire - Thu Dec 19, 5:38AM CST

OCGN : 0.7743 (+0.83%)
Ocugen's Dr. Shankar Musunuri to Present at Oppenheimer Movers in Rare Disease Summit Discussing Advances in Retinal Disease Therapies Quiver Quantitative, Inc. - Wed Dec 11, 4:18PM CST

Ocugen's CEO will present at a rare disease summit, highlighting advancements in gene therapies for inherited retinal diseases.Quiver AI SummaryOcugen, Inc., a biotechnology company focused on innovative...

OCGN : 0.7743 (+0.83%)
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit GlobeNewswire - Wed Dec 11, 6:02AM CST

OCGN : 0.7743 (+0.83%)
Ocugen, Inc. CEO Dr. Shankar Musunuri to Present at NobleCon20 Emerging Growth Equity Conference Quiver Quantitative, Inc. - Wed Nov 27, 4:32PM CST

Ocugen's CEO will present at NobleCon20 on December 3, discussing the company's clinical programs and growth strategies.Quiver AI SummaryOcugen, Inc. announced that Dr. Shankar Musunuri, the company's...

OCGN : 0.7743 (+0.83%)
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference GlobeNewswire - Wed Nov 27, 6:09AM CST

OCGN : 0.7743 (+0.83%)
Ocugen, Inc. Receives Orphan Medicinal Product Designation from EMA for OCU410ST in Treating ABCA4-Associated Retinopathies Quiver Quantitative, Inc. - Wed Nov 20, 4:48PM CST

Ocugen's OCU410ST receives orphan designation from EMA for treating rare retinal diseases, advancing towards clinical trials and potential market approval.Quiver AI SummaryOcugen, Inc. announced that the...

OCGN : 0.7743 (+0.83%)
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease GlobeNewswire - Wed Nov 20, 6:30AM CST

OCGN : 0.7743 (+0.83%)
Ocugen, Inc. Reports Positive Preliminary Data from OCU410 Clinical Trial for Geographic Atrophy in Dry Age-Related Macular Degeneration Quiver Quantitative, Inc. - Tue Nov 19, 4:16PM CST

Ocugen announced positive early results for OCU410 in treating geographic atrophy, showing safety and efficacy.Quiver AI SummaryOcugen, Inc. announced promising preliminary results from the Phase 1 dose-escalation...

OCGN : 0.7743 (+0.83%)
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GlobeNewswire - Tue Nov 19, 6:02AM CST

OCGN : 0.7743 (+0.83%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot